To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

Bill: 117-hr-7640
Sponsor: full_name: Rep. Bilirakis, Gus M. [R-FL-12]
Introduced: 2022-05-03
Policy area: Health
Latest action: action_date: 2022-05-03
text: Referred to the House Committee on Energy and Commerce.

Summaries:
action_date: 2022-05-03
action_desc: Introduced in House
text: <p>This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.</p>

tv_txt: I 117th CONGRESS 2d Session H. R. 7640 IN THE HOUSE OF REPRESENTATIVES May 3, 2022 Mr. Bilirakis (for himself and Mr. Butterfield ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as orphan drugs ).

1. Reauthorization of grants and contracts for development of orphan drugs Section 5(c) of the Orphan Drug Act ( 21 U.S.C. 360ee(c) ) is amended by striking 2018 through 2022 and inserting 2023 through 2027 .